Ceros Ltd. is delving deep into the biology of the hypothalamus to develop therapeutics for osteoporosis and obesity. The company believes its biological focus will enable it to transit from an observed phenotype in animal models to targets underlying the phenotype, an approach it expects to link target to both pharmacological action and therapeutic effect.

"When I was head of biology and genetics at SmithKline Beecham, I saw a gap between the genome's potential targets and what comes out the other end," said President and CEO Sohaila Rastan. "This gap will lead to a collapse in drug development if it's not addressed."